洛匹那韦药代动力学的研究进展

姚亚敏; 沐俊; 孙骥; 马芳; 卢洪洲; 张丽军

doi:10.3969/j.issn.1006-0111.2012.05.005

洛匹那韦药代动力学的研究进展

doi: 10.3969/j.issn.1006-0111.2012.05.005

1.
上海市公共卫生临床中心, 上海 201508
2.
苏州大学医学部, 江苏苏州 215123

基金项目: 抗艾滋病病毒新药临床评价研究技术平台建设(2012ZX09303013);成人艾滋病适宜治疗策略研究与应用(2012ZX10001003)

Progress on pharmacokinetics of lopinavir

1.
Shanghai Public Health Clinical Center, Shanghai 201508, China
2.
Medical College of Suzhou University, Suzhou 215123, China

摘要: 洛匹那韦作为第二代蛋白酶抑制剂,在艾滋病治疗领域得到广泛应用。然而,该药能被代谢酶CYP3A4快速代谢,在临床应用中,存在较大的个体差异。因此,对洛匹那韦进行药代动力学分析,了解其血药浓度与疗效以及不良反应的关系对优化临床用药具有重要意义。本文全面综述了近年来洛匹那韦浓度分析方法、药代动力学研究进展,为日后洛匹那韦治疗药物监测以及个体化用药研究提供归纳总结材料。
- 洛匹那韦 /
- 艾滋病 /
- 蛋白酶抑制剂 /
- 药代动力学
Abstract: Lopinavir was widely used as a second generation protease inhibitor in AIDS therapy, which was quickly metabolized by CYP3A4. For individual variance might lead to different metabolism, it was important to study the pharmacokinetic parameters of lopinavir and learn the relationship between drug concentration and curative effect or adverse reactions. The methods for determining lopinavir concentration and the progress of pharmacokinetic research were reviewed in this paper which might offer some help for treatment drug monitoring (TDM) and personalized dosage research.
- lopinavir /
- AIDS /
- protease inhibitor /
- pharmacokinetics

[1]	Faux J, Venisse N, Olivie PJ,et al. Rapid high-performance liquid chromatography determination of lopinavir, a novel HIV-1 protease inhibitor, in human plasma[J]. Chromatographia, 2001, 54:469.
[2]	Jaspervander L,Anchalee A.clinical pharmacology and pharmacokinetics of antiretrovirals in Asia[J]. Asian Biomedicine,2009,3(1):53.
[3]	Eric D,Veronique R, Francois R, et al. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients[J]. Eur J Clin Pharmacol,2005,61:153.
[4]	Matthias G, Stephanie R, Stephanie L,et al. Pharmacogenomic adaptation of antiretroviral therapy:overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism[J]. Eur J Clin Pharmacol,2010,66:107.
[5]	Rajasekhar D, Jaswanthumar I, Ravik, et al. Simultaneous determination of ritonavir and lopinavir in human plasma after protein precipitation and LC-MS-MS[J]. Chromatographia, 2010, 71:815.
[6]	Difrancesco R, Dicenzo R, Vicente G, et al. Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry[J]. J Pharm Biomed Anal, 2007, 44 (5):1139.
[7]	Frerichs VA, Difrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 787(2):393.
[8]	Perry GW, Jack SW, Grace K, et al. Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma usingsemi-automated 96-well liquid-liquid extraction[J]. J Chromatogr A, 2006,1130:302.
[9]	Yoshiko USAMI, Tsuyoshi OKI, Masahiko NAKAI, et al.A simple HPLC method for simultaneous determination of lopinavir,ritonavir and efavirenz[J]. Chem Pharm Bull,2003, 51(6):715.
[10]	Rita CEE, Fabio SR, Brayan VS, et al.Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasmaultra-filtrate by liquid chromatography/tandem mass spectrometry detection[J]. Rapid Commun Mass Spectrom,2008,22:657.
[11]	Manuela E, Marion M, Walter EH, et al. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay[J]. J Chromatogr B, 2007, 850:249.
[12]	Manish Y, Rajasekhar R, Hemal K,et al. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects[J]. J Pharmaceut Biomed,2009, 49:1115.
[13]	Heinea R,Rosinga H,Gorpb ECM,et al.Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry[J]. J Chromatogr B,2008,867:208.
[14]	Yao Y,Sun J,Chen J,et al.LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma[J]. Acta Pharmaceut Sin,2010, 45 (2):279.
[15]	Slish JC,Catnzaro LM, Ma Q,et al. Update on the pharmacokinetic aspects of antiretroviral agents:implications in therapeutic drug monitoring[J]. Current Pharmaceutical Design, 2006, 12:1129.
[16]	Van Heeswijk RPG, Bourbeau M, Seguin I, et al. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients[J]. Br J Clin Pharmacol, 2005, 59 (4):398.
[17]	Gondi NK, Venkata KJ, Marianne KJ,et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans[J]. Pharmacol Res, 2004, 21(9):1622.
[18]	Jackson A, Hill A, Puls R,et al.Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers[J]. J Antimicro Chemoth,2011,66(3):635.
[19]	Ann H, Jeffrey I, Scott B. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients[J]. Antimicrob Agents Ch,2003, 47(1):350.
[20]	Natella R, John A, Aline B, et al.Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children[J]. Antimicrob Agents Ch,2009, 53(6):2532.

[1]	江冼芮, 段雅倩, 刘畅, 张成中. 淫羊藿中黄酮苷类化合物的群体感应抑制作用研究 . 药学实践与服务, 2025, 43(4): 1-5. doi: 10.12206/j.issn.2097-2024.202409060
[2]	冯一帆, 严啸东, 张文彬, 李炳锋, 郭美丽. 菸花苷长期给药对脑缺血再灌注损伤大鼠神经功能的影响 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202407038
[3]	崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华. 肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2025, 43(1): 6-9, 21. doi: 10.12206/j.issn.2097-2024.202404006
[4]	魏雨辰, 田家盛, 王道鑫, 凌期盛, 王治, 缪朝玉. 烟酰胺单核苷酸口服给药对高血压大鼠的影响 . 药学实践与服务, 2025, 43(5): 1-9. doi: 10.12206/j.issn.2097-2024.202412006
[5]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[6]	彭莹, 刘欣, 聂依文, 王歆荷, 年华, 朱建勇. 三种狼毒乙醇提取物对咪喹莫特诱导的银屑病小鼠防治作用研究 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202406029
[7]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[8]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[9]	冯婷婷, 张景翔, 王彦, 许维恒, 张俊平. ANXA3基因及蛋白的研究进展 . 药学实践与服务, 2025, 43(2): 47-50, 74. doi: 10.12206/j.issn.2097-2024.202309023
[10]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[11]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[12]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[13]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[14]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[15]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[16]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[17]	张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳. 基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
[18]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[19]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
[20]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082

期刊类型引用(0)
其他类型引用(3)

点击查看大图

计量

文章访问数: 4715
HTML全文浏览量: 345
PDF下载量: 1416
被引次数: 3

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

洛匹那韦药代动力学的研究进展

doi: 10.3969/j.issn.1006-0111.2012.05.005

Progress on pharmacokinetics of lopinavir

期刊类型引用(0)

其他类型引用(3)

计量

洛匹那韦药代动力学的研究进展

doi: 10.3969/j.issn.1006-0111.2012.05.005

1. 上海市公共卫生临床中心, 上海 201508

2. 苏州大学医学部, 江苏苏州 215123

English Abstract

Progress on pharmacokinetics of lopinavir

1. Shanghai Public Health Clinical Center, Shanghai 201508, China

2. Medical College of Suzhou University, Suzhou 215123, China

全文HTML

目录

全文HTML

留言板

洛匹那韦药代动力学的研究进展

doi: 10.3969/j.issn.1006-0111.2012.05.005

Progress on pharmacokinetics of lopinavir

期刊类型引用(0)

其他类型引用(3)

计量

出版历程

洛匹那韦药代动力学的研究进展

doi: 10.3969/j.issn.1006-0111.2012.05.005

1. 上海市公共卫生临床中心, 上海 201508 2. 苏州大学医学部, 江苏 苏州 215123

English Abstract

Progress on pharmacokinetics of lopinavir

1. Shanghai Public Health Clinical Center, Shanghai 201508, China 2. Medical College of Suzhou University, Suzhou 215123, China

全文HTML

目录

全文HTML

1. 上海市公共卫生临床中心, 上海 201508

2. 苏州大学医学部, 江苏苏州 215123

1. Shanghai Public Health Clinical Center, Shanghai 201508, China

2. Medical College of Suzhou University, Suzhou 215123, China